| [1] |
Reck M, Heigener DF, Mok T, et al. Management of non-small-cell lung cancer: recent developments[J]. Lancet, 2013, 382(9893):709-719. DOI: 10.1016/S0140-6736(13)61502-0.
doi: 10.1016/S0140-6736(13)61502-0
|
| [2] |
Morgensztern D, Ng SH, Gao F, et al. Trends in stage distribution for patients with non-small cell lung cancer: a national cancer database survey[J]. J Thorac Oncol, 2010, 5(1):29-33. DOI: 10.1097/JTO.0b013e3181c5920c.
doi: 10.1097/JTO.0b013e3181c5920c
pmid: 19952801
|
| [3] |
Mittal V. Epithelial mesenchymal transition in tumor metastasis[J]. Annu Rev Pathol, 2018, 13:395-412. DOI: 10.1146/annurev-pathol-020117-043854.
doi: 10.1146/annurev-pathol-020117-043854
pmid: 29414248
|
| [4] |
Saito A, Horie M, Nagase T. TGF-β signaling in lung health and disease[J]. Int J Mol Sci, 2018, 19(8):2460. DOI: 10.3390/ijms19082460.
doi: 10.3390/ijms19082460
|
| [5] |
Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan[J]. Nat Rev Mol Cell Biol, 2012, 13(4):225-238. DOI: 10.1038/nrm3293.
|
| [6] |
Grbesa I, Pajares MJ, Martínez-Terroba E, et al. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients[J]. PLoS One, 2015, 10(4): e0124670. DOI: 10.1371/journal.pone.0124670.
|
| [7] |
Cha BK, Kim YS, Hwang KE, et al. Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1[J]. Oncotarget, 2016, 7(35):57213-57227. DOI: 10.18632/oncotarget.11127.
doi: 10.18632/oncotarget.v7i35
|
| [8] |
Banerji U. Heat shock protein 90 as a drug target: some like it hot[J]. Clin Cancer Res, 2009, 15(1):9-14. DOI: 10.1158/1078-0432.CCR-08-0132.
doi: 10.1158/1078-0432.CCR-08-0132
pmid: 19118027
|
| [9] |
Silva GT, Bergmann A, Thuler LC. Incidence, associated factors, and survival in metastatic spinal cord compression secondary to lung cancer[J]. Spine J, 2015, 15(6):1263-1269. DOI: 10.1016/j.spinee.2015.02.015.
doi: 10.1016/j.spinee.2015.02.015
|
| [10] |
Nguyen MT, Somogyvári M, Sõti C. Hsp90 stabilizes SIRT1 orthologs in mammalian cells and C. elegans[J]. Int J Mol Sci, 2018, 19(11):3661. DOI: 10.3390/ijms19113661.
doi: 10.3390/ijms19113661
|
| [11] |
陈万青, 左婷婷, 郑荣寿, 等. 2013年中国肺癌发病与死亡分析[J]. 中华肿瘤杂志, 2017, 39(10):795-800. DOI: 10.3760/cma.j.issn.0253-3766.2017.10.015.
|
| [12] |
Bhattarai B, Schmidt MF, Ghosh M, et al. Lung cancer with skin and breast metastasis: a case report and literature review[J]. Case Rep Pulmonol, 2015, 2015:136970. DOI: 10.1155/2015/136970.
doi: 10.1155/2015/136970
pmid: 25861506
|
| [13] |
Yang S, Liu Y, Li MY, et al. FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer[J]. Mol Cancer, 2017, 16(1): 124. DOI: 10.1186/s12943-017-0700-1.
|
| [14] |
Fang Y, Nicholl MB. A dual role for sirtuin 1 in tumorigenesis[J]. Curr Pharm Des, 2014, 20(15):2634-2636. DOI: 10.2174/13816128113199990488.
doi: 10.2174/13816128113199990488
|
| [15] |
Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism[J]. Trends Endocrinol Metab, 2014, 25(3):138-145. DOI: 10.1016/j.tem.2013.12.001.
doi: 10.1016/j.tem.2013.12.001
|
| [16] |
Noh SJ, Baek HA, Park HS, et al. Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer[J]. Pathol Res Pract, 2013, 209(6):365-370. DOI: 10.1016/j.prp.2013.03.011.
doi: 10.1016/j.prp.2013.03.011
|
| [17] |
Ye Z, Fang B, Pan J, et al. miR-138 suppresses the proliferation, metastasis and autophagy of non-small cell lung cancer by targeting Sirt1[J]. Oncol Rep, 2017, 37(6):3244-3252. DOI: 10.3892/or.2017.5619.
doi: 10.3892/or.2017.5619
|
| [18] |
Chatterjee S, Huang EH, Christie I, et al. Acquired resistance to the Hsp90 inhibitor, ganetespib, in KRAS-mutant NSCLC is mediated via reactivation of the ERK-p90RSK-mTOR signaling network[J]. Mol Cancer Ther, 2017, 16(5):793-804. DOI: 10.1158/1535-7163.MCT-16-0677.
doi: 10.1158/1535-7163.MCT-16-0677
|
| [19] |
Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic[J]. Lancet Oncol, 2013, 14(9):e358-e369. DOI: 10.1016/S1470-2045(13)70169-4.
doi: 10.1016/S1470-2045(13)70169-4
|
| [20] |
Sibinska Z, Tian X, Korfei M, et al. Amplified canonical transforming growth factor-β signalling via heat shock protein 90 in pulmonary fibrosis[J]. Eur Respir J, 2017, 49(2): 1501941. DOI: 10.1183/13993003.01941-2015.
doi: 10.1183/13993003.01941-2015
|